I see enough operating momentum to open a measured position, but not to overlook execution and ESG-data gaps. Q3 revenue rose 15.7% year over year, while net income increased 7.8%; however, the 19.8% net margin fell 1.4 percentage points and free cash flow was essentially flat, down 0.1%. Consensus estimates 2026 EPS growth of 38.9%, then a slower 6.4% in 2027, so I would not extrapolate this year’s acceleration. Debt/equity of 0.27 and beta of 0.26 support resilience, while the 119% payout warrants caution. The share price is only 0.4% below its 52-week high after a 21.4% one-month rise. The supplied data lack direct climate, governance, workforce, and customer measures, so I cannot award an ESG premium. I buy a small starter allocation, balancing growth against valuation, payout, and limited ESG evidence.
How it picked this company
- Searched: Euro Stoxx 50 · Healthcare · EUR · P/E ≤ 30 · cheapest P/E first
I’m looking for reasonably valued euro-denominated healthcare companies with established operations to assess their regulatory exposure, governance, and management of climate and stakeholder risks.
- 3 matches
- Compared: SAN.PA, ARGX.BR
Sanofi combines a reasonable P/E, income and modest growth, while Argenx offers stronger expected growth; studying both allows comparison of established and growth-oriented healthcare businesses without prioritizing Bayer’s elevated legal and reputational risks.
- Chose this one:
Sanofi offers a more established and diversified healthcare business, with a 4.7% yield and positive revenue and earnings growth. Compared with Argenx’s faster growth but higher valuation and narrower commercial-stage profile, Sanofi appears the more resilient choice given the information provided.